Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 11/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911463 | 0.83 | CA12 (0.56) | SUCNR1ITGB3ITGA2BCA1CA2 | |
| SCHEMBL911228 | 0.83 | CA1 (0.46) | SUCNR1ITGB3ITGA2BCA1CA2 | |
| SCHEMBL917117 | 0.82 | CA1 (0.54) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL30521147 | 0.81 | CA1 (0.60) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL910749 | 0.80 | ITGB3 (0.52) | SUCNR1ITGB3ITGA2B | |
| SCHEMBL29107778 | 0.79 | MEN1 (0.60) | SUCNR1ITGB3ITGA2BCA1CA2 | |
| SCHEMBL7300004 | 0.79 | ITGB3 (0.64) | SUCNR1ITGB3ITGA2BCA1CA2 | |
| SCHEMBL5015557 | 0.79 | CA1 (0.59) | SUCNR1ITGB3ITGA2BCA1CA2 | |
| SCHEMBL910539 | 0.79 | CA1 (0.62) | SUCNR1ITGB3ITGA2BCA1CA2 | |
| SCHEMBL3174253 | 0.79 | CA1 (0.53) | SUCNR1ITGB3ITGA2BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-1922073-B1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8211895-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1922073-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007018640-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | SUCNR1 3570/4885ITGB3 2862/4885ITGA2B 1900/4885 |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | SUCNR1 3570/4885ITGB3 2862/4885ITGA2B 1900/4885 |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | SUCNR1 3570/4885ITGB3 2862/4885ITGA2B 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.